A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF COMBINATION ANTIRETROVIRAL REG

组合抗逆转录病毒药物 REG 的 II/III 期随机、开放标签研究

• 批准号: 7606800
• 负责人: Yvonne J. Bryson
• 金额: $ 0.22万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-21 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606800
• 关键词: Anti-Retroviral Agents; Computer Retrieval of Information on Scientific Projects Database; End Point; Failure; Funding; Grant; Institution; Label; Phase; Protease Inhibitor; Randomized; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Viral Load result; non-nucleoside reverse transcriptase inhibitors

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS The primary objectives are: ¿ To compare the combination of 2 NRTIs plus a protease inhibitor (PI) versus 2 NRTIs plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) as initial therapy, followed by second-line therapy if failure occurs, in terms of their effects on a long-term virologic endpoint. ¿ To compare two different viral load criteria for switching from first-line to second-line therapy.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标 主要目标是： ¿ 比较2种NRTI+一种蛋白酶抑制剂（PI）与2种NRTI+一种非核苷类逆转录酶抑制剂（NNRTI）联合治疗作为初始治疗，如果失败，则进行二线治疗对长期病毒学终点的影响。 ¿ 比较从一线治疗转换为二线治疗的两种不同病毒载量标准。